Italy’s Sorin Group has issued a press release in which it confirms it will be participating in the manufacture of Boston Scientific’s Lotus™ transcatheter heart valve. The news is seen as confirmation that the device will soon gain its first regulatory approval, with CE marking expected later in 2013.
Background
The Lotus transcatheter aortic valve is another embodiment of the metal scaffold with biological valve core. It was originally developed by Sadra Medical and saw its first implantation as far back as 2007, subsequent to which the company was acquired by Boston Scientific.
The terms of the new agreement between Boston and Sorin have not been disclosed, other than to confirm that certain components for the valve will be supplied from the Italian outfit’s Vancouver site.
Read more about the competitive landscape into which Lotus will eventually be a player by clicking here to our sister site, Cardiodevicenews.com.
Source: Sorin Group
published: July 16, 2013 in: Boston Scientific, Cardio, News, Sorin